MRK
Merck & Co., Inc.
NYSE: MRK · Rahway, NJ · Healthcare
$145.27-1.97 (-1.34%)Closed
Market Cap$358.41B
Cash$7.14Bmost recent
Runwayprofitable
P/E (TTM)20.0EPS $7.28
52-Wk Range$80.14 – $155.53
Avg Volume11.3M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$145.27+46.5%
Pipeline

Drug candidates sponsored by Merck & · ClinicalTrials.gov

91 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4MK0869, aprepitant / Duration of Treatment: 3 days
Nausea+1 more
Completed
2004-09-30past
1
Phase 4Gonal-f
Infertility
Completed
2006-01-16past
1
Phase 4AzaSite (azithromycin ophthalmic solution)
Bacterial Infections+1 more
Completed
2008-10past
1
Phase 4Infliximab
Spondylitis, Ankylosing+1 more
Terminated
2008-11past
1
Phase 4Nirogacestat
Desmoid Tumor+1 more
Recruiting
2031-02-26
1
Phase 3Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
Measles+3 more
Completed
2001-10past
1
Phase 3Rocuronium bromide (Org 9426)
Muscle Relaxation
Completed
2003-12past
1
Phase 3V501
Human+1 more
Completed
2005-11-03past
1
Phase 3Esmirtazapine
Postmenopausal Symptoms+2 more
Completed
2006-01-15past
1
Phase 3MK0507A, dorzolamide hydrochloride (+) timolol maleate
Glaucoma+1 more
Completed
2006-07past
1
Phase 3Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine
Neoplasms, Glandular and Epithelial+4 more
Completed
2007-04past
1
Phase 3Zoster Vaccine, Live, (Oka-Merck)
Varicella Virus Infection
Completed
2007-05past
1
Phase 3MK0524A, /Duration of Treatment : 4 Weeks
Flushing
Completed
2007-08past
1
Phase 3Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
Papillomavirus Infections
Completed
2008-02-04past
1
Phase 3Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)
Measles+3 more
Terminated
2008-05past
1
Phase 3Rebif®
Clinically Isolated Syndrome
Completed
2008-11past
1
Phase 3Comparator: fosaprepitant dimeglumine
Chemotherapy-Induced Nausea and Vomiting (CINV)
Completed
2009-06past
1
Phase 3Acadesine
Coronary Artery Bypass+4 more
Terminated
2010-10past
1
Phase 3Sitagliptin phosphate
Type 2 Diabetes
Completed
2010-10-04past
1
Phase 3Preladenant 2 mg tablet
Parkinson Disease
Completed
2012-12-20past
1
Phase 3CXA-201
Complicated Urinary Tract Infection+1 more
Completed
2013-08-11past
1
Phase 3Ipragliflozin
Type 2 Diabetes Mellitus
Completed
2017-03-07past
1
Phase 3V212
Herpes Zoster
Completed
2017-04-11past
1
Phase 39vHPV vaccine
Papillomavirus Infections+5 more
Completed
2019-01-29past
1
Phase 3Placebo
Chronic Cough
Completed
2020-06-05past
1
Phase 3Prevnar 13™
Pneumococcal Infections
Completed
2020-12-14past
1
Phase 3Rotarix™
Pneumococcal Infections
Completed
2021-08-05past
1
Phase 2Pembrolizumab
Non Small Cell Lung Cancer (NSCLC)+8 more
Active, not recruiting
2027-01-31
10
Phase 2Posaconazole oral suspension
Mycoses
Completed
2001-11past
1
Phase 2MK0826, ertapenem sodium /Duration of Treatment: 14 Days
Urinary Tract Infections+2 more
Completed
2003-12past
1
Phase 2Org 34517
Depression+2 more
Completed
2006-07past
1
Phase 2Sugammadex
Anesthesia, General
Completed
2006-08-31past
1
Phase 2MK0533
Diabetes Mellitus Type 2
Terminated
2007-08past
1
Phase 2MK0893
Diabetes Mellitus, Type 2
Terminated
2008-05past
1
Phase 2MK0249
Paranoid Schizophrenia
Completed
2008-10past
1
Phase 2UFOX + Cetuximab
Previously Untreated Metastatic Colorectal Cancer
Completed
2009-06past
1
Phase 2MK-0941
Type 2 Diabetes Mellitus
Completed
2010-05past
1
Phase 2Vicriviroc
HIV Infections
Completed
2010-05past
1
Phase 2Placebo to Ertuglilflozin 1 or 5 mg
Diabetes Mellitus, Type 2+1 more
Completed
2011-02-09past
1
Phase 2Cetuximab
Colorectal Neoplasms
Completed
2014-12past
1
Phase 2luspatercept
B-Thalassemia
Completed
2015-11-11past
1
Phase 2ATX-MS-1467
Multiple Sclerosis
Completed
2016-04-30past
1
Phase 2Grazoprevir
Hepatitis C
Completed
2016-09-16past
1
Phase 2Islatravir
HIV-1 Infection
Completed
2022-03-18past
1
Phase 2MK-3795
VHL Gene Mutation+10 more
Completed
2023-08-30past
1
Phase 2Olaparib
Solid Tumors
Completed
2026-06-08past
1
Phase 1Coformulated favezelimab/pembrolizumab
Metastatic Urothelial Carcinoma+1 more
Active, not recruiting
2027-05-31
1
Phase 2Zilovertamab vedotin
Lymphoma, Large B-Cell, Diffuse
Recruiting
2027-12-13
1
Phase 2Pembrolizumab (+) Berahyaluronidase alfa
Classical Hodgkin Lymphoma Recurrent+3 more
Active, not recruiting
2028-11-08
1
Phase 1coformulation pembrolizumab/quavonlimab
Small Cell Lung Carcinoma
Active, not recruiting
2029-12-10
1
Phase 2Intismeran autogene
Urinary Bladder Neoplasms+2 more
Recruiting
2031-09-03
1
Phase 2Indinavir sulfate
HIV Infections
Unknown—1
Phase 2valopicitabine
Chronic Hepatitis C
Completed—1
Phase 1V520
HIV-1+1 more
Completed
2006-10past
1
Phase 1vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin
Advanced Cancer
Completed
2007-12past
1
Phase 1MK0731
Cancer
Completed
2008-01past
1
Phase 1ridaforolimus
Cancer+1 more
Completed
2008-07past
1
Phase 1MK2461
Advanced Cancer
Completed
2008-12past
1
Phase 1Comparator: Testosterone 300 mg, intramuscular injection
Muscle Anabolism
Completed
2008-12past
1
Phase 1MK0752
Healthy
Completed
2009-01past
1
Phase 1Comparator: amlodipine besylate
Hypertension
Completed
2009-02past
1
Phase 1Comparator: Placebo 5mg (run in)
Alzheimer's Disease
Completed
2009-10past
1
Phase 1ACE-031
Muscular Atrophy
Completed
2011-02past
1
Phase 1MK-0873 Patch
Plaque Psoriasis
Completed
2011-03-01past
1
Phase 1EMD 1201081 + 5-FU + Cisplatin + Cetuximab
Squamous Cell Carcinoma of the Head and Neck
Terminated
2011-04past
1
Phase 1MK-5108
Cancer, Neoplasms, Tumors
Completed
2011-04-04past
1
Phase 1Unnamed
Insomnia
Completed
2011-09-01past
1
Phase 1Unnamed
Advanced Pancreatic Adenocarcinoma
Terminated
2012-05past
1
Phase 1Vorinostat
Relapsed or Refractory Multiple Myeloma
Completed
2012-09-03past
1
Phase 1MK-7680
Hepatitis C
Completed
2015-02past
1
Phase 1PT2385
Healthy
Completed
2015-11past
1
Phase 1Methadone
Human Immunodeficiency Virus (HIV) Infection
Completed
2016-06-13past
1
Phase 1Ceftolozane/Tazobactam - Multiple Doses
Critically Ill+1 more
Completed
2017-06-15past
1
Phase 1Belzutifan
Healthy
Completed
2018-05-26past
1
Phase 1MK-8558
HIV-1 Infection
Completed
2020-05-29past
1
Phase 1MK-6552
Healthy+1 more
Completed
2023-11-20past
1
Phase 1Pembrolizumab Dose C
Melanoma
Completed
2023-12-04past
1
Phase 1MK-7602
Malaria
Completed
2025-01-06past
1
Phase 1MK-2225
Systemic Sclerosis
Completed
2025-07-14past
1
Phase 1MK-8527
Healthy
Completed
2026-07-31past
1
Phase 1MK-4082
Healthy
Completed
2026-09-01past
1
Phase 1MK-1403 + additive coformulation
Diabetes Mellitus, Type 2
Completed
2026-09-02past
1
Phase 1MK-4002
Multiple Myeloma in Relapse+3 more
Active, not recruiting
2026-12-31
1
Phase 1MK-8294
Metastatic Neoplasm
Recruiting
2029-07-01
1
Phase 1Cyclophosphamide (CPA)
Non-small Cell Lung Cancer (NSCLC) Stage III
Withdrawn—1
N/AUnnamed
Arthritis, Rheumatoid
Terminated
2006-10past
1
N/APegIntron (peginterferon alfa-2b; SCH 54031) injector
Hepatitis C, Chronic+1 more
Completed
2009-06past
1
N/AUnnamed
Human Papillomavirus Infection
Completed
2010-12-13past
1
N/AUnnamed
Infertility
Completed
2012-01past
1
N/AUnnamed
Colorectal Neoplasms
Completed
2013-08past
1
N/AUnnamed
Human Papillomavirus Infections
Completed
2014-12-02past
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for MRK. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.